Cited by 377Antifungal resistance and susceptibilityFungal Infections and StudiesFungal Plant Pathogen Control

The DOI matches its Crossref record; 922 of the 930 references it cites were found in a registry or an index.

Clinical Pharmacology of Systemic Antifungal Agents: A Comprehensive Review of Agents in Clinical Use, Current Investigational Compounds, and Putative Targets for Antifungal Drug Development

Groll, Andreas H., Piscitelli, Stephen C., Walsh, Thomas J.·1998·Advances in pharmacology

DOI 10.1016/s1054-3589(08)60129-5

Open this paper in CoChat — free account

Integrity signals

Registry

Crossref · 10.1016/s1054-3589(08)60129-5

Cites

922 of 922 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Principles and Practice of Infectious Diseases.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-818_5 · Cited by 12,045
A Receptor-Mediated Pathway for Cholesterol Homeostasis
Brown, M. S., & Goldstein, J. L. (1986) · Science · doi:10.1126/science.3513311 · Cited by 5,703
Regulation of the mevalonate pathway
Goldstein, J. L., & Brown, M. S. (1990) · Nature · doi:10.1038/343425a0 · Cited by 5,394
ABC Transporters: From Microorganisms to Man
Higgins, C. F. (1992) · Annual Review of Cell Biology · doi:10.1146/annurev.cb.08.110192.000435 · Cited by 3,985
POLYAMINES
Tabor, C. W., & Tabor, H. (1984) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.53.070184.003533 · Cited by 3,111
DNA TOPOISOMERASE POISONS AS ANTITUMOR DRUGS
Liu, L. F. (1989) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.58.070189.002031 · Cited by 1,805
Cell Wall Chemistry, Morphogenesis, and Taxonomy of Fungi
Bartnicki-García, S. (1968) · Annual Review of Microbiology · doi:10.1146/annurev.mi.22.100168.000511 · Cited by 1,569
A Controlled Trial of Fluconazole to Prevent Fungal Infections in Patients Undergoing Bone Marrow Transplantation
Goodman, J. L., Winston, D. J., Greenfield, R. A., Chandrasekar, P. H., Fox, B. C., Kaizer, H., Shadduck, R. K., Shea, T. C., Stiff, P. J., Friedman, D. J., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199203263261301 · Cited by 1,164
Secular Trends in the Epidemiology of Nosocomial Fungal Infections in the United States, 1980-1990
Beck‐Sagué, C. M., Jarvis, W. R., & System, N. N. I. S. (1993) · The Journal of Infectious Diseases · doi:10.1093/infdis/167.5.1247 · Cited by 1,140
Peptide antibiotics
Hancock, R. E. W. (1997) · The Lancet · doi:10.1016/s0140-6736(97)80051-7 · Cited by 1,098

Show all 930 references

Research works printed but not linked: 18

Atkinson, 1969, Pharmacokinetics of intrathecal administered amphotericin B., Am. Rev. Respir. Dis., 99, 917
Benhamu, 1991, Does ketoconazole prevent fungal infection in children treated with high-dose chemotherapy and bone-marrow transplantation?, Bone Marrow Transplant., 7, 127
Bernardo, 1994, The effect of L-arginine on amphotericin B-induced nephrotoxicity., J. Am. Soc. Nephrol., 5, 917
Brammer, 1987, A review of the pharmacokinetics of fluconazole (UK-49,858) in laboratory animals and man, 141
Feldman, 1992, The use of granulocyte-stimulating factor (GCSF) enhanced granulocyte transfusions from normal donors in patients with neutropenia related fungal infections, Blood, 80, 414a
G. Gaenger, G. Just-Nuebling, M. Eichel, R. Hoika, W. Stille (1993). Itraconazole solution in patients with non-response to fluconazole. In Abstracts of the IXth International Conference on AIDS, abstract 1394.
Gascoigne, 1981, The kinetics of ketoconazole in animals and man., Clin. Res. Rev., 1, 177
Gelfand, 1988, Amphotericin B treatment of human mononuclear cells in vitro results in secretion of tumor necrosis factor and interleukin-1., Clin. Res., 36, 456
Graybill, 1982, Ketoconazole therapy for systemic fungal infections: Inadequacy of standard dose regimens., Am. Rev. Respir. Dis., 126, 171
Gupta, 1994, Antifungal agents: An overview. Part II., J. Am. Acad. Dermatol., 30, 911, 10.1016/S0190-9622(94)70112-1 · DOI
Hiemenz, 1995, Emergency use of amphotericin B lipid complex (ABLC) in the treatment of patients with aspergillosis historical control comparison with amphotericin B, Blood, 86, 849a
Jolidon, 1993, 2,3 oxidosqualene-lanosterol cyclase, an attractive target for antifungal drug design.
Moore, 1995, Hematopoietic reconstitution: New approaches., Clin. Cancer Res., 1, 3
Peeters, 1986, Itraconzole, a new orally active triazole derivative for treatment of vaginal candidosis., Curr. Ther. Res., 39, 496
Plempel, 1988, Antimycotic effects of BAY R 3783 in vitro and on dermatophytoses and opportunistic mycoses of the organs in vivo, Rev. lb. Micol., 5, 0
Ringden, 1993, Clinical experience with AmBisome with special emphasis on experience with children., Bone Marrow Transplant., 12, S149
Schaude, 1988, Biological activity of SDZ 89485 in animal models., Rev. lb. Micol., 5, P51
Shepard, 1986, Cyclosporin-ketoconazole: A potentially dangerous drug interaction., Clin. Pharmacol., 6, 468

Sorted by citations

Clinical Practice Guidelines for the Management Candidiasis: 2009 Update by the Infectious Diseases Society of America
Pappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191
Self-citation
Guidelines for Treatment of Candidiasis
Pappas, P. G., Rex, J. H., Sobel, J. D., Filler, S. G., Dismukes, W. E., Walsh, T. J., & Edwards, J. E. (2004) · Clinical Infectious Diseases · doi:10.1086/380796 · Cited by 1,440
Practice Guidelines for the Treatment of Candidiasis
Rex, J. H., Walsh, T. J., Sobel, J. D., Filler, S. G., Pappas, P. G., Dismukes, W. E., & Edwards, J. E. (2000) · Clinical Infectious Diseases · doi:10.1086/313749 · Cited by 927
Invasive Aspergillosis Disease Spectrum, Treatment Practices, and Outcomes
Patterson, T. F., Kirkpatrick, W. R., White, M., Hiemenz, J. W., WINGARD, J. R., DUPONT, B., RINALDI, M. G., STEVENS, D. A., & Graybill, J. R. (2000) · Medicine · doi:10.1097/00005792-200007000-00006 · Cited by 791
Zygomycosis in a Tertiary‐Care Cancer Center in the Era of Aspergillus‐ Active Antifungal Therapy: A Case‐Control Observational Study of 27 Recent Cases
Kontoyiannis, D. P., Lionakis, M. S., Lewis, R. E., Chamilos, G., Healy, M., Perego, C., Safdar, A., Kantarjian, H. M., Champlin, R. E., Walsh, T. J., et al. (2005) · The Journal of Infectious Diseases · doi:10.1086/428780 · Cited by 674
Mechanisms of Antifungal Drug Resistance
Cowen, L. E., Sanglard, D., Howard, S. J., Rogers, P. D., & Perlin, D. S. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a019752 · Cited by 647
Infections due to emerging and uncommon medically important fungal pathogens
Walsh, T. J., Groll, A. H., Hiemenz, J., Fleming, R. V., Roilides, E., & Anaissie, E. J. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1470-9465.2004.00839.x · Cited by 600
Antifungal drug resistance of pathogenic fungi
Kontoyiannis, D. P., & Lewis, R. E. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08162-x · Cited by 553
Antifungal Susceptibility Testing: Practical Aspects and Current Challenges
Rex, J. H., Pfaller, M. A., Walsh, T. J., Chaturvedi, V., Espinel-Ingroff, A., Ghannoum, M. A., Gosey, L. L., Odds, F. C., Rinaldi, M. G., Sheehan, D. J., et al. (2001) · Clinical Microbiology Reviews · doi:10.1128/cmr.14.4.643-658.2001 · Cited by 444
Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children
WALSH, T. J., LUTSAR, I., DRISCOLL, T., DUPONT, B., RODEN, M., GHAHRAMANI, P., HODGES, M., GROLL, A. H., & PERFECT, J. R. (2002) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-200203000-00015 · Cited by 431
Primary Central Nervous System Phaeohyphomycosis: A Review of 101 Cases
Revankar, S. G., Sutton, D. A., & Rinaldi, M. G. (2004) · Clinical Infectious Diseases · doi:10.1086/380635 · Cited by 403
Safety, Tolerance, and Pharmacokinetics of High-Dose Liposomal Amphotericin B (AmBisome) in Patients Infected with Aspergillus Species and Other Filamentous Fungi: Maximum Tolerated Dose Study
Walsh, T. J., Goodman, J. L., Pappas, P. G., Bekersky, I., Buell, D. N., Roden, M. M., Barrett, J., & Anaissie, E. J. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.12.3487-3496.2001 · Cited by 401
Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients
Bellmann, R., & Smuszkiewicz, P. (2017) · Infection · doi:10.1007/s15010-017-1042-z · Cited by 418
Current Concepts in Antifungal Pharmacology
Lewis, R. E. (2011) · Mayo Clinic Proceedings · doi:10.4065/mcp.2011.0247 · Cited by 391
ESCMID and ECMM joint clinical guidelines for the diagnosis and management of systemic phaeohyphomycosis: diseases caused by black fungi
Chowdhary, A., Meis, J. F. G. M., Guarro, J., de Hoog, S., Kathuria, S., Arendrup, M. C., Arıkan-Akdağlı, S., Akova, M., Boekhout, T., Caira, M., et al. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12515 · Cited by 381
Comparative Efficacy and Distribution of Lipid Formulations of Amphotericin B in Experimental Candida albicans Infection of the Central Nervous System
Groll, A. H., Giri, N., Petraitis, V., Petraitienė, R., Candelario, M., Bacher, J., Piscitelli, S. C., & Walsh, T. J. (2000) · The Journal of Infectious Diseases · doi:10.1086/315643 · Cited by 373
Candida Infections and Therapeutic Strategies: Mechanisms of Action for Traditional and Alternative Agents
Santos, G. C. D. O., Vasconcelos, C. C., Lopes, A. J. O., Cartágenes, M. D. S. D. S., Filho, A. K. D. B., do Nascimento, F. R. F., Ramos, R. M., Pires, E. R. R. B., de Andrade, M. S., Rocha, F. M. G., et al. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01351 · Cited by 381
Cinnamaldehyde and its derivatives, a novel class of antifungal agents
Shreaz, S., Wani, W. A., Behbehani, J. M., Raja, V., Irshad, M., Karched, M., Ali, I., Siddiqi, W. A., & Hun, L. T. (2016) · Fitoterapia · doi:10.1016/j.fitote.2016.05.016 · Cited by 355
Pharmacokinetics, Excretion, and Mass Balance of Liposomal Amphotericin B (AmBisome) and Amphotericin B Deoxycholate in Humans
Bekersky, I., Fielding, R. M., Dressler, D. E., Lee, J. W., Buell, D. N., & Walsh, T. J. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.3.828-833.2002 · Cited by 323
Pharmacology of Systemic Antifungal Agents
Ashley, E. S. D., Lewis, R. E., Lewis, J. S., Martin, C. A., & Andes, D. R. (2006) · Clinical Infectious Diseases · doi:10.1086/504492 · Cited by 317
Uncommon opportunistic fungi: new nosocomial threats
Groll, A. H., & Walsh, T. J. (2001) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2001.tb00005.x · Cited by 304
Emerging fungal pathogens: evolving challenges to immunocompromised patients for the twenty‐first century
Walsh, T. J., & Groll, A. H. (1999) · Transplant Infectious Disease · doi:10.1034/j.1399-3062.1999.010404.x · Cited by 294
Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies
Kontoyiannis, D. P., Hachem, R. Y., Lewis, R. E., Rivero, G., Torres, H. A., Thornby, J. A., Champlin, R., Kantarjian, H. M., Bodey, G. P., & RAAD, I. I. (2003) · Cancer · doi:10.1002/cncr.11479 · Cited by 287
Morpholine as ubiquitous pharmacophore in medicinal chemistry: Deep insight into the structure-activity relationship (SAR)
Kumari, A., & Singh, R. K. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.103578 · Cited by 253
Evolutionary Emergence of Drug Resistance in Candida Opportunistic Pathogens
Ksiezopolska, E., & Gabaldón, T. (2018) · Genes · doi:10.3390/genes9090461 · Cited by 230
Preclinical Assessment of the Efficacy of Mycograb, a Human Recombinant Antibody against Fungal HSP90
Matthews, R., Rigg, G. P., Hodgetts, S. J., Carter, T., Chapman, C. J., Gregory, C. A., Illidge, C., & Burnie, J. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.7.2208-2216.2003 · Cited by 232
Population Pharmacokinetic Analysis of Voriconazole Plasma Concentration Data from Pediatric Studies
Karlsson, M. O., Lutsar, I., & Milligan, P. A. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00751-08 · Cited by 228
Genome-wide expression profiling of the response to polyene, pyrimidine, azole, and echinocandin antifungal agents in Saccharomyces cerevisiae.
Agarwal, A. K., Rogers, P. D., Baerson, S. R., Jacob, M. R., Barker, K. S., Cleary, J. D., Walker, L. A., Nagle, D. G., & Clark, A. M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306291200 · Cited by 204
Current and future antifungal therapy: new targets for antifungal agents
Andriole, V. T. (1999) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/44.2.151 · Cited by 191
Synthesis and antimicrobial activity of N-alkyl and N-aryl piperazine derivatives
Chaudhary, P. M., Kumar, R., Verma, A. K., Singh, D., Yadav, V., Chhillar, A. K., Sharma, G. L., & Chandra, R. (2005) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.10.032 · Cited by 187
Clinical hepatotoxicity associated with antifungal agents
Kyriakidis, I., Tragiannidis, A., Munchen, S., & Groll, A. H. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1270264 · Cited by 191
Antifungal Efficacy of Caspofungin (MK-0991) in Experimental Pulmonary Aspergillosis in Persistently Neutropenic Rabbits: Pharmacokinetics, Drug Disposition, and Relationship to Galactomannan Antigenemia
Petraitienė, R., Petraitis, V., Groll, A. H., Sein, T., Schaufele, R. L., Francesconi, A., Bacher, J., Avila, N. A., & Walsh, T. J. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.1.12-23.2002 · Cited by 182
Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model
Andes, D., Stamsted, T., & Conklin, R. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.3.922-926.2001 · Cited by 180
Antifungal Activity and Pharmacokinetics of Posaconazole (SCH 56592) in Treatment and Prevention of Experimental Invasive Pulmonary Aspergillosis: Correlation with Galactomannan Antigenemia
Petraitienė, R., Petraitis, V., Groll, A. H., Sein, T., Piscitelli, S. C., Candelario, M., Field‐Ridley, A., Avila, N. A., Bacher, J., & Walsh, T. J. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.3.857-869.2001 · Cited by 179
The Pharmacokinetics and Pharmacodynamics of Micafungin in Experimental HematogenousCandidaMeningoencephalitis: Implications for Echinocandin Therapy in Neonates
Hope, W. W., Mickiene, D., Petraitis, V., Petraitienė, R., Kelaher, A. M., Hughes, J. E., Cotton, M. P., Bacher, J., Keirns, J. J., Buell, D. N., et al. (2007) · The Journal of Infectious Diseases · doi:10.1086/524063 · Cited by 177
Advances in synthetic approach to and antifungal activity of triazoles
Shalini, K., Kumar, N., Drabu, S., & Sharma, P. K. (2011) · Beilstein Journal of Organic Chemistry · doi:10.3762/bjoc.7.79 · Cited by 173
Current challenges in the management of invasive fungal infections
Lai, C., Tan, C., Huang, Y., Shao, P., & Hsueh, P. (2008) · Journal of Infection and Chemotherapy · doi:10.1007/s10156-007-0595-7 · Cited by 167
Antifungal Drug Resistance in Aspergillus
Moore, C. B., Sayers, N. M., Mosquera, J., Slaven, J. W., & Denning, D. W. (2000) · Journal of Infection · doi:10.1053/jinf.2000.0747 · Cited by 162
New targets and delivery systems for antifungal therapy
Walsh, T. J., Viviani, M. A., Arathoon, E., Chiou, C. C., Ghannoum, M. A., Groll, A. H., & Odds, F. C. (2000) · Medical Mycology · doi:10.1080/mmy.38.s1.335.347 · Cited by 163
Clinical pharmacology of antifungal compounds
Groll, A. H., Gea‐Banacloche, J., Glasmacher, A., Just‐Nübling, G., Maschmeyer, G., & Walsh, T. J. (2003) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(02)00068-5 · Cited by 157
Novel antifungals and treatment approaches to tackle resistance and improve outcomes of invasive fungal disease
Hoenigl, M., Arastehfar, A. A., Arendrup, M. C., Brüggemann, R. J. M., Carvalho, A., Chiller, T. M., Chen, W., Egger, M., Feys, S., Gangneux, J., et al. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00074-23 · Cited by 165
Ciclopirox Olamine Treatment Affects the Expression Pattern ofCandida albicansGenes Encoding Virulence Factors, Iron Metabolism Proteins, and Drug Resistance Factors
Niewerth, M., Kunze, D., Seibold, M., Schaller, M., Körting, H. C., & Hube, B. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.6.1805-1817.2003 · Cited by 145
The efficacy of self-assembled cationic antimicrobial peptide nanoparticles against Cryptococcus neoformans for the treatment of meningitis
Wang, H., Xu, K., Liu, L., Tan, J. P. K., Chen, Y., Li, Y., Fan, W., Wei, Z., Sheng, J., Yang, Y. Y., et al. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2009.12.042 · Cited by 138
Diagnosis and therapy of Candida infections: joint recommendations of the German Speaking Mycological Society and the Paul-Ehrlich-Society for Chemotherapy
Ruhnke, M., Rickerts, V., Cornely, O. A., Buchheidt, D., Glöckner, A., Heinz, W., Höhl, R., Horré, R., Karthaus, M., Kujath, P., et al. (2011) · Mycoses · doi:10.1111/j.1439-0507.2011.02040.x · Cited by 140
Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections
Groll, A. H., & Walsh, T. J. (2001) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.10.8.1545 · Cited by 137
Pharmacokinetic and Pharmacodynamic Modeling of Anidulafungin (LY303366): Reappraisal of Its Efficacy in Neutropenic Animal Models of Opportunistic Mycoses Using Optimal Plasma Sampling
Groll, A. H., Mickiene, D., Petraitienė, R., Petraitis, V., Lyman, C. A., Bacher, J., Piscitelli, S. C., & Walsh, T. J. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.10.2845-2855.2001 · Cited by 137
Clinical Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of Liposomal Amphotericin B
Groll, A. H., Rijnders, B. J. A., Walsh, T. J., Adler‐Moore, J., Lewis, R. E., & Brüggemann, R. J. M. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz076 · Cited by 140
Antifungal activity of essential oils and their synergy with fluconazole against drug-resistant strains of Aspergillus fumigatus and Trichophyton rubrum
Khan, M. S., & Ahmad, I. (2011) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-011-3152-3 · Cited by 127
Programmed cell death in pathogenic fungi
Ramsdale, M. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2008.01.021 · Cited by 126
An antisense-based functional genomics approach for identification of genes critical for growth of Candida albicans
Backer, M. D. D., Nelissen, B., Logghe, M., Viaene, J., Loonen, I., Vandoninck, S., Hoogt, R. D., Dewaele, S., Simons, F. A., Verhasselt, P., et al. (2001) · Nature Biotechnology · doi:10.1038/85677 · Cited by 124
The Future of Antifungal Drug Therapy: Novel Compounds and Targets
Mota Fernandes, C., Dasilva, D., Haranahalli, K., McCarthy, J. B., Mallamo, J., Ojima, I., & Del Poeta, M. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01719-20 · Cited by 124
Safety, Pharmacokinetics, and Pharmacodynamics of Cyclodextrin Itraconazole in Pediatric Patients with Oropharyngeal Candidiasis
Groll, A. H., Wood, L., Roden, M., Mickiene, D., Chiou, C. C., Townley, E., Dad, L., Piscitelli, S. C., & Walsh, T. J. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.8.2554-2563.2002 · Cited by 123
The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy
Wiederhold, N. P., & Lewis, R. E. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.8.1313 · Cited by 144
New Drugs and Novel Targets for Treatment of Invasive Fungal Infections in Patients with Cancer
Chiou, C. C., Groll, A. H., & Walsh, T. J. (2000) · The Oncologist · doi:10.1634/theoncologist.5-2-120 · Cited by 124
Disruption of the Candida albicans TPS2 Gene Encoding Trehalose-6-Phosphate Phosphatase Decreases Infectivity without Affecting Hypha Formation
Dijck, P. V., Rop, L. D., Szlufcik, K., Ael, E. V., & Thevelein, J. M. (2002) · Infection and Immunity · doi:10.1128/iai.70.4.1772-1782.2002 · Cited by 119
Synergy, Pharmacodynamics, and Time-Sequenced Ultrastructural Changes of the Interaction between Nikkomycin Z and the Echinocandin FK463 against Aspergillus fumigatus
Chiou, C. C., Mavrogiorgos, N., Tillem, E., Hector, R., & Walsh, T. J. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.12.3310-3321.2001 · Cited by 117
Self-citation
Rationale for Combination Antifungal Therapy
Lewis, R. E., & Kontoyiannis, D. P. (2001) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.21.12.149s.34505 · Cited by 116
Recent developments of metal-based compounds against fungal pathogens
Lin, Y., Betts, H. D., Keller, S., Cariou, K., & Gasser, G. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00945h · Cited by 116
Posaconazole: clinical pharmacology and potential for management of fungal infections
Groll, A. H., & Walsh, T. J. (2005) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.3.4.467 · Cited by 114
Comparison between liposomal formulations of amphotericin B
Adler‐Moore, J., Gangneux, J., & Pappas, P. G. (2016) · Medical Mycology · doi:10.1093/mmy/myv111 · Cited by 113
Analysis of macrolide antibiotics, using liquid chromatography‐mass spectrometry, in food, biological and environmental matrices
Wang, J. (2008) · Mass Spectrometry Reviews · doi:10.1002/mas.20189 · Cited by 113
Population Pharmacokinetics of Amphotericin B Lipid Complex in Neonates
Würthwein, G., Groll, A. H., Hempel, G., Adler‐Shohet, F. C., Lieberman, J. M., & Walsh, T. J. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.12.5092-5098.2005 · Cited by 108
Recent Developments in Molecular Genetics of Candida Albicans
Backer, M. D. D., Magee, P. T., & Plá, J. (2000) · Annual Review of Microbiology · doi:10.1146/annurev.micro.54.1.463 · Cited by 109
Triad of Acute Infusion‐Related Reactions Associated with Liposomal Amphotericin B: Analysis of Clinical and Epidemiological Characteristics
Roden, M. M., Nelson, L. D., Knudsen, T. A., Jarosinski, P. F., Starling, J. M., Shiflett, S. E., Calis, K. A., DeChristoforo, R., Donowitz, G. R., Buell, D. N., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/374553 · Cited by 109
Fungal infections after bone marrow transplant
Wingard, J. R. (1999) · Transplantation and Cellular Therapy · doi:10.1053/bbmt.1999.v5.pm10371357 · Cited by 109
Recent Approaches to Antifungal Therapy for Invasive Mycoses
Mathew, B. P., & Nath, M. (2009) · ChemMedChem · doi:10.1002/cmdc.200800353 · Cited by 105
Antifungals: From Pharmacokinetics to Clinical Practice
do Carmo, A., Rocha, M. J., Pereirinha, P., Tomé, R., & Costa, E. (2023) · Antibiotics · doi:10.3390/antibiotics12050884 · Cited by 115
Amphotericin B Encapsulated in Micelles Based on Poly(ethylene oxide)-block-poly( l -amino acid) Derivatives Exerts Reduced in Vitro Hemolysis but Maintains Potent in Vivo Antifungal Activity
Adams, M. L., Andes, D. R., & Kwon, G. S. (2003) · Biomacromolecules · doi:10.1021/bm0257614 · Cited by 103
Antifungal Activities of Antineoplastic Agents: Saccharomyces cerevisiae as a Model System To Study Drug Action
Cardenas, M. E., Cruz, M. C., Poeta, M. D., Chung, N., Perfect, J. R., & Heitman, J. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.4.583 · Cited by 103
Infections in the Neutropenic Patient— New Views of an Old Problem
Donowitz, G. R., Maki, D. G., Crnich, C. J., Pappas, P. G., & Rolston, K. V. I. (2001) · Hematology · doi:10.1182/asheducation-2001.1.113 · Cited by 98
Brain abscess due toCladophialophora bantiana: a review of 124 cases
Chakrabarti, A., Kaur, H., Rudramurthy, S. M., Appannanavar, S. B., Patel, A. K., Mukherjee, K. K., Ghosh, A. K., & Ray, U. (2015) · Medical Mycology · doi:10.1093/mmy/myv091 · Cited by 99
Azole Resistance In Aspergillus Fumigatus : A New Challenge In The Management Of Invasive Aspergillosis?
Snelders, E., Melchers, W. J. G., & Verweij, P. E. (2011) · Future Microbiology · doi:10.2217/fmb.11.4 · Cited by 98
Current and future antifungal therapy: New targets for antifungal therapy
Andriole, V. T. (2000) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(00)00258-2 · Cited by 97
Systemic mycoses in the immunocompromised host: an update in antifungal therapy
Kontoyiannis, D. P., Mantadakis, E., & Samonis, G. (2003) · Journal of Hospital Infection · doi:10.1053/jhin.2002.1278 · Cited by 98
Perspective on Plant Products as Antimicrobials Agents: A Review
Pandey, A. K., & Kumar, S. (2013) · Pharmacologia · doi:10.5567/pharmacologia.2013.469.480 · Cited by 95
Antifungal Therapy for Systemic Mycosis and the Nanobiotechnology Era: Improving Efficacy, Biodistribution and Toxicity
Souza, A. C. O., & Amaral, A. C. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.00336 · Cited by 94
Antifungal Activity and Mechanism of Action of the Co(III) Coordination Complexes With Diamine Chelate Ligands Against Reference and Clinical Strains of Candida spp.
Turecka, K., Chylewska, A., Kawiak, A., & Waleron, K. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01594 · Cited by 94
Novel antifungal drugs
DiDomenico, B. (1999) · Current Opinion in Microbiology · doi:10.1016/s1369-5274(99)00009-0 · Cited by 91
Environmental fungicides and triazole resistance in Aspergillus
Bowyer, P., & Denning, D. W. (2013) · Pest Management Science · doi:10.1002/ps.3567 · Cited by 87
CNS Aspergillosis
Ruhnke, M., Kofla, G., Otto, K., & Schwartz, S. (2007) · CNS Drugs · doi:10.2165/00023210-200721080-00004 · Cited by 87
Antifungals in Systemic Neonatal Candidiasis
Frattarelli, D. A. C., Reed, M. D., Giacoia, G. P., & Aranda, J. V. (2004) · Drugs · doi:10.2165/00003495-200464090-00003 · Cited by 82
Toward more effective antifungal therapy: the prospects of combination therapy
Kontoyiannis, D. P., & Lewis, R. E. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05007.x · Cited by 85
Preclinical Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antifungal Activity of Liposomal Amphotericin B
Adler‐Moore, J., Lewis, R. E., Brüggemann, R. J. M., Rijnders, B. J. A., Groll, A. H., & Walsh, T. J. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz064 · Cited by 85
Evaluation of Mycograb®, amphotericin B, caspofungin, and fluconazole in combination against Cryptococcus neoformans by checkerboard and time-kill methodologies
Nooney, L., Matthews, R., & Burnie, J. (2005) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2004.08.013 · Cited by 83
Synthesis and in vitro activity of 2-thiazolylhydrazone derivatives compared with the activity of clotrimazole against clinical isolates of Candida spp.
Chimenti, F., Bizzarri, B., Maccioni, E., Secci, D., Bolasco, A., Fioravanti, R., Chimenti, P., Granese, A., Carradori, S., Rivanera, D., et al. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.05.078 · Cited by 82
Clinical relevance of mechanisms of antifungal drug resistance in yeasts
Sanglard, D. (2002) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/s0213-005x(02)72842-5 · Cited by 80
Antifungal peptides produced by actinomycetes and their biological activities against plant diseases
Zhang, D., Lu, Y., Chen, H., Wu, C., Zhang, H., Chen, L., & Chen, X. (2020) · The Journal of Antibiotics · doi:10.1038/s41429-020-0287-4 · Cited by 82
Comparative Efficacies of Four Amphotericin B Formulations—Fungizone, Amphotec (Amphocil), AmBisome, and Abelcet—against Systemic Murine Aspergillosis
Clemons, K. V., & Stevens, D. A. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.3.1047-1050.2004 · Cited by 77
Visualizing fungal infections in living mice using bioluminescent pathogenic Candida albicans strains transformed with the firefly luciferase gene
Doyle, T. C., Nawotka, K. A., Bellinger-Kawahara, C., Francis, K. P., & Contag, P. R. (2006) · Microbial Pathogenesis · doi:10.1016/j.micpath.2005.11.003 · Cited by 76
Antifungal chemotherapy: advances and perspectives
Groll, A. H., & Walsh, T. J. (2002) · Swiss Medical Weekly · doi:10.4414/smw.2002.09729 · Cited by 76
A Recent Overview of 1,2,3-Triazole-Containing Hybrids as Novel Antifungal Agents: Focusing on Synthesis, Mechanism of Action, and Structure-Activity Relationship (SAR)
Marzi, M., Farjam, M., Kazeminejad, Z., Shiroudi, A., Kouhpayeh, S. A., & Zarenezhad, E. (2022) · Journal of Chemistry · doi:10.1155/2022/7884316 · Cited by 74
Antifungal Pharmacodynamics: Concentration‐Effect Relationships in Vitro and in Vivo
Groll, A. H., Piscitelli, S. C., & Walsh, T. J. (2001) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.21.12.133s.34507 · Cited by 73
Antifungal Agents: In Vitro Susceptibility Testing, Pharmacodynamics, and Prospects for Combination Therapy
Groll, A. H., & Kolve, H. (2004) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-004-1108-6 · Cited by 72
Invasive fungal infections in acute leukemia
Bhatt, V. R., Viola, G. M., & Ferrajoli, A. (2011) · Therapeutic Advances in Hematology · doi:10.1177/2040620711410098 · Cited by 71
The Exciting Future of Antifungal Therapy
Neely, M. N., & Ghannoum, M. A. (2000) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s100960000395 · Cited by 71
Screening of antifungal activity of plants from the northeast of Mexico
Garza, B. A. A., González-González, G. M., Salazar‐Aranda, R., de Torres, N. H. W., & Rivas-Galindo, V. M. (2007) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2007.08.026 · Cited by 70
Antifungal resistance in dermatology
Pai, V. V., Ganavalli, A., & Kikkeri, N. (2018) · Indian Journal of Dermatology · doi:10.4103/ijd.ijd_131_17 · Cited by 69
Recombinant antibodies: a natural partner in combinatorial antifungal therapy
Matthews, R., & Burnie, J. (2003) · Vaccine · doi:10.1016/j.vaccine.2003.11.032 · Cited by 69
Itraconazole-Amphotericin B Antagonism in Aspergillus fumigatus : an E-Test-Based Strategy
Kontoyiannis, D. P., Lewis, R. E., Sagar, N., May, G. S., Prince, R. A., & Rolston, K. V. I. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.10.2915-2918.2000 · Cited by 69
Coprisin-induced antifungal effects in Candida albicans correlate with apoptotic mechanisms
Lee, J., Hwang, J.-S., Hwang, I.-S., Cho, J., Lee, E., Kim, Y., & Lee, D. G. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.03.012 · Cited by 64

Authors: Groll, A. H., Piscitelli, S. C., & Walsh, T. J.
Affiliations: National Institutes of Health (US)
ORCID: Groll, Andreas H.
Piscitelli, Stephen C.
Walsh, Thomas J.
Venue: Advances in pharmacology
Publisher: Elsevier
Published: 1998
Volume: 44
Pages: 343-500
ISSN: 1054-3589 (ISSN-L)
DOI: 10.1016/s1054-3589(08)60129-5
OpenAlex: W63281979
Cited by: 377
References: 930
Citations by year: 2026: 3 · 2025: 3 · 2024: 16 · 2023: 7 · 2022: 12 · 2021: 8 · 2020: 13 · 2019: 7 · 2018: 8 · 2017: 10 · 2016: 13 · 2015: 13 · 2014: 16 · 2013: 13 · 2012: 7
FWCI: 54.29
Type: book chapter
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Advances in pharmacology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
Keywords: systemic antifungal agents, clinical pharmacology, antifungal drug development, antifungal drug targets, fungal infection
MeSH terms: Animals, Antifungal Agents, Fungi, Humans, Mycoses, Triazoles

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Clinical Pharmacology of Systemic Antifungal Agents: A Comprehensive Review of Agents in Clinical Use, Current Investigational Compounds, and Putative Targets for Antifungal Drug Development

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks